Does glycoprotein IIB/IIIA resistance exist?

Smit, Jjj; Hof, Arnoud W J van ‘t

doi:10.1007/bf03086016

Cited by 1 publication

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The term antiplatelet 'resistance' is used to describe different phenomena such as (1) inability to prevent thrombotic complications, (2) failure to inhibit platelet aggregation by in vitro platelet function tests, (3) insufficient inhibition of plasma or urinary biochemical markers for platelet aggregation [Smit and Van 'T Hof, 2007]. A recently published meta-analysis showed that aspirin-resistant patients are at greater risk of clinical important cardiovascular morbidity long term than patients who are sensitive to aspirin [Krasopoulos et al 2008].…”

Section: Resistance To Antiplatelet Drugsmentioning

confidence: 99%

Clinical pharmacology of antithrombotic drugs in coronary artery disease

Fauler

2009

Therapeutic Advances in Cardiovascular Disease

View full text Add to dashboard Cite

Coronary heart disease is the leading cause of death in the Western world. Antithrombotic therapy is the cornerstone of its successful treatment. Clinical trials have demonstrated that antithrombotic therapy reduces the risk for recurrent myocardial infarction and cardiovascular death. Antiplatelet drugs and anticoagulants interfere with haemostasis and thus bleeding is a major risk factor of these drugs. The benefit of antithrombotic therapy must therefore be carefully balanced with the risk of bleeding and other potential adverse reactions of these drugs. However, to date there is no firm evidence that dosage adaptation of aspirin or clopidogrel according to platelet aggregation testing translates directly into any clinical benefit. Resistance to antithrombotic drugs is a serious problem because these patients are at a higher risk of myocardial infarction, stroke and cardiovascular death. It has most recently been demonstrated that resistance to clopidogrel is at least in part caused by polymorphism of CYP2C19. Clinical trials have also demonstrated that optimal benefit in different settings depends unequivocally on the meticulous choice of the various drugs. Thus, profound knowledge of the clinical pharmacological profiles of the different antithrombotic drugs is indispensable for successful treatment.

show abstract

Section: Resistance To Antiplatelet Drugsmentioning

confidence: 99%

Clinical pharmacology of antithrombotic drugs in coronary artery disease

Fauler

2009

Therapeutic Advances in Cardiovascular Disease

View full text Add to dashboard Cite

show abstract

Does glycoprotein IIB/IIIA resistance exist?

Cited by 1 publication

References 17 publications

Clinical pharmacology of antithrombotic drugs in coronary artery disease

Clinical pharmacology of antithrombotic drugs in coronary artery disease

Contact Info

Product

Resources

About